Clinique des Céphalées de Montréal

Quick facts

Phase 2 pipeline

• Erenumab Auto-Injector · Neurology
  Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Clinique des Céphalées de Montréal portfolio CI brief
• Clinique des Céphalées de Montréal pipeline updates RSS

Related

• Sector hub: All tracked pharma companies